RECENT NEWS

As part of its commitment to public health, bioMérieux has announced two upcoming events focused on sepsis and the blood culture pathway. The Irish Sepsis Summit takes place 21 June in Athlone, with the UK Sepsis Summit following on 5-6 September, at the University of Nottingham.

The NHS is set to introduce a new genetic blood-matching test for thousands living with sickle cell disease or thalassaemia that could reduce some of the side effects of transfusion treatments.

UK company X-Lab has launched a successful pilot of its Labgnostic software between TriCore and Arkana Labs to enable interoperability between diagnostic laboratories. X-Lab which owns and operates a systems-agnostic laboratory exchange hub, called Labgnostic, has recently gone 'live' in connecting the first two US laboratories to the network.

Sphere Fluidics, a company developing single-cell analysis systems underpinned by its patented picodroplet technology, has recently revealed its new branding to align with its ambitious global commercial growth strategy.

Digital pathology solutions and clinical AI firm Paige has introduced new advanced integration capabilities to the Paige Platform, a holistic web-based solution that enables complete digital pathology workflows and supports the evolving needs of today’s modern laboratory.

Revvity has announced a new licence agreement with AstraZeneca for the technology underlying its Pin-point base editing system, a next-generation modular gene editing platform with a strong safety profile.

Lonza has launched the new TheraPEAK T-VIVO cell culture medium, a novel chemically defined medium developed to optimise CAR T-cell manufacture.

The British In Vitro Diagnostics Association (BIVDA) has today launched a new independent white paper, ‘Leveraging advanced diagnostics to realise the UK's potential in genomics’ which examines the UK genomics landscape, with a focus on patient access to genomic testing.

SHOT, MHRA and UKTLC are pleased to announce a joint webinar covering the importance of learning from incidents and the principles of investigating incidents.

More than £70 million has been granted to Health Data Research UK (HDR UK) by some of the largest government and charity research funders in the UK.

Leading clinical diagnostics firm Beckman Coulter has unveiled the DxI 9000 Access Immunoassay Analyser, the most productive immunoassay analyser per footprint, capable of running up to 215 tests per hour per square metre.

Randox has unveiled two new launches, a prostate-specific antigen (PSA) which allows testing for indications of prostate cancer and other prostate conditions, as well as a an automated test for levels of B-type natriuretic peptide (BNP), a protein made in the heart and blood vessels, elevated levels of which are indicative of several co-morbid conditions.

The Institute of Cancer Research, London, and its hospital partner The Royal Marsden NHS Foundation Trust have announced the opening of their new joint Integrated Pathology Unit (IPU). England’s first centre of its kind is set to make significant improvements in cancer diagnosis and treatment – by combining pioneering digital imaging with artificial intelligence.

Action must be taken now to stop the UK from losing its exceptional strengths in health research, and the value it brings to society, says a new report published by the Academy of Medical Sciences.

Genomics and Precision Medicine Expo – taking place on 23-24 May 2023 at ExCeL London – has announced its top 5 ‘not to be missed’ highlights for this year’s inaugural conference.

Cleanroom microbiology company Cherwell will be launching a new portable biofluorescence particle counter (BFPC) to the UK and Ireland at the forthcoming Cleanroom Technology Conference 2023.

Siemens Healthineers has entered into an agreement to distribute Scopio Labs' full-field digital cell morphology technology, which will enable clinical laboratorians to examine patient blood-cell samples digitally instead of under a microscope.

Pfizer and Thermo Fisher Scientific have announced they have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable.

Revvity has been officially launched as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere. The company was previously affiliated with PerkinElmer.

The British In Vitro Diagnostics Association (BIVDA) commissioned the University of Nottingham to produce an independent White Paper examining the UK Government’s procurement of COVID-19 tests during the pandemic, which has now been published.